Plain-English translation of NCT02625909 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hepatitis C research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested a hepatitis C medication called SOF/VEL to see if a shorter 6-week course could work as well as the standard 12-week course in treating people with recently acquired hepatitis C. The study included people who inject drugs and people with HIV coinfection—two groups that historically have been harder to treat and have higher rates of hepatitis C infection.
Hepatitis C is spreading rapidly in certain communities, particularly among people who inject drugs and men with HIV. This medication represents a major advance because it doesn't require interferon (an older, harder-to-tolerate treatment), but doctors needed to understand whether shorter treatment courses could work just as well, which might encourage more people to accept treatment and prevent the infection from becoming chronic.
Participants in this trial took one tablet of the medication once daily for either 6 or 12 weeks (the assignment was random, though both the participants and study staff initially didn't know which duration they had been assigned to until week 6). Participants attended study visits for medical monitoring, blood tests, and questionnaires to assess how well the medication worked and how safe it was. The trial followed participants to see whether the virus was completely eliminated and whether the infection did not return.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States
Australia